Johnson & Johnson Starts New Late Stage COVID-19 Vaccine Trial
Johnson & Johnson will study the potential benefits of a second dose.
Johnson & Johnson has started a new late stage trial to begin testing a two-dose regimen of its experimental COVID-19 vaccine. It will study potential benefits of a second dose.
The drug maker plans to have up to 30,000 participants for the study. A one-dose trial study had around 60,000 people.
Last week, drugmakers Pfizer and Bio-N-Tech said its potential vaccine showed more than 90 percent effective rate.
'Don't Say Gay' Florida Lawmaker Indicted On Fraud Charges
Florida Rep. Joe Harding is being charged with two counts of wire fraud, two counts of money laundering and two counts of making false statements.By Phelan M. Ebenhack / AP
Doctors: Get Your Flu, COVID Vaccines Now To Be Safe During Holidays
There's more room for the flu and COVID to spread as restrictions subside, but not as many people are up to date on their vaccines either.By Ted S. Warren / AP
China Eases Anti-COVID Measures Following Protests
China is the last major country still trying to stamp out transmission of the virus while many nations switch to trying to live with it.By Ng Han Guan / AP
Democratic Sen. Kyrsten Sinema Switches To Independent
Sen. Kyrsten Sinema said she was “declaring my independence from the broken partisan system in Washington.”By Scott Applewhite / AP
House Passes Defense Bill Scrapping COVID Vaccine Mandate
The bill provides nearly $858 billion for national defense in addition to taking away a COVID vaccine mandate for U.S. military members.By Ted S. Warren / AP
New Abnormal: Climate Disaster Damage 'Down' To $268 Billion
Many — but not all – weather disasters are being turbocharged by human-caused climate change and are happening more frequently.By Zahid Hussain / AP